Freya has developed and demonstrated GPX-501 - Bimatoprost eluting contact lenses to provide sustained release resulting in therapeutic concentrations for extended durations, eliminating the peaks and troughs in concentrations from drops, which may cause sub-therapeutic concentration between drop instillations, which can lead to infection proliferation and/or development of resistance